FED CUTS Fed slashes interest rates by 25 basis points in 2nd consecutive cut LSE - Delayed Quote ? GBp Oxford BioDynamics Plc (OBD.L) Follow Compare 1.1800 -0.0700 (-5.60%) At close: 4:35 PM GMT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Oxford Biodynamics to present on its line of EpiSwitch? products for companion diagnostics in cancer immunotherapy at the 14th World Summit for Clinical Biomarkers and Companion Diagnostics in Boston, MA. OXFORD, England, July 25, 2024--Oxford BioDynamics, Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on the EpiSwitch? 3D genomics platform [1], announces its key-note presentation at the 14th World Summit for Clinical Biomarkers and Companion Diagnostics, taking place on 3-6 September 2024 in Boston, MA, USA. Business Wire ? 3 months ago OXBOF Oxford BioDynamics part of consortium shortlisted for Strategic Government Initiative to Improve Cancer Immunotherapy OXFORD, England, June 25, 2024--Oxford BioDynamics, Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on OBD’s EpiSwitch? 3D genomics platform,[4] announces that it has formed a strategic consortium which has been shortlisted for the UK Government’s Checkpoint Inhibitor Response Research Platform (CIRRP) award call for biomarker development around immunotherapies of cancer. If successful, the consortium’s Business Wire ? 4 months ago OXBOF Oxford BioDynamics Develops a High Accuracy, Discriminating Diagnostic Test for Multiple Canine Cancers OXFORD, England, June 04, 2024--Oxford BioDynamics Plc (AIM: OBD, the "Company"), a biotechnology company developing precision medicine tests based on the EpiSwitch? 3D genomics platform, announces development of a high-accuracy, discriminating multi-cancer canine diagnostic test for veterinary medicine. Business Wire ? 5 months ago OXBOF Is Oxford BioDynamics (LON:OBD) In A Good Position To Deliver On Growth Plans? Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... Simply Wall St. ? 9 months ago OXBOF Performance Overview Trailing total returns as of 11/7/2024, which may include dividends or other distributions. Benchmark is FTSE 100 Return OBD.L FTSE 100 YTD -95.79% +5.27% 1-Year -96.42% +9.75% 3-Year -97.46% +11.46%
